深圳市龙岗区社区女性人乳头瘤病毒疫苗的接种现状及其影响因素分析

职业与健康 ›› 2025, Vol. 41 ›› Issue (15): 2042-2046.

深圳市龙岗区社区女性人乳头瘤病毒疫苗的接种现状及其影响因素分析

蔡松涛¹, 梁文涛², 林锦波³, 黄向辉², 洪国庆⁴

1.香港中文大学（深圳）附属第二医院/深圳市龙岗区人民医院全科医学科,广东深圳 518100;
2.深圳市龙岗中心医院同德社康中心,广东深圳 518100;
3.深圳市龙岗区骨科医院龙园大观社康中心,广东深圳 518100;
4.遵义医科大学珠海校区,广东珠海 519090

收稿日期:2024-10-05 修回日期:2024-10-15 出版日期:2025-08-15 发布日期:2025-12-12
通信作者: 梁文涛,主治医师,E-mail：13714810986@163.com
作者简介:蔡松涛,男,主治医师,主要从事社区常见疾病诊疗和慢病管理工作。
基金资助:
深圳市龙岗区医疗卫生科技计划项目（LGWJ2022-20）; 深圳市龙岗区经济与科技发展专项资金医疗卫生项目（LGKCYLWS2021000010）

Analysis of the current status and influencing factors of human papillomavirus vaccination among community women in Longgang District of Shenzhen

CAI Songtao¹, LIANG Wentao², LIN Jinbo³, HUANG Xianghui², HONG Guoqin⁴

1. Department of General Practice, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People’s Hospital of Shenzhen, Shenzhen, Guangdong 518100, China;
2. Tongde Community Health Center, Shenzhen Longgang Central Hospital, Shenzhen, Guangdong 518100, China;
3. Longyuan Daguan Community Health Center, Shenzhen Longgang Orthopedics Hospital, Shenzhen, Guangdong 518100, China;
4. Zhuhai Campus of Zunyi Medical University, Zhuhai, Guangdong 519090, China

Received:2024-10-05 Revised:2024-10-15 Online:2025-08-15 Published:2025-12-12
Contact: LIANG Wentao,Attending physician,E-mail：13714810986@163.com

摘要/Abstract

摘要： 目的了解深圳市社区女性人乳头瘤病毒疫苗（human palillomavirus,HPV）预防接种现状及其影响因素,为HPV疫苗在社区女性中的更好推广提供参考依据。方法采用便利抽样和分层整群抽样相结合的方法,选取深圳市龙岗区6个街道社区的1 208名女性为调查对象,2023年9—12月对抽样人群进行有关HPV疫苗接种现状及其影响因素的问卷调查,并对数据进行分析。结果纳入的研究对象平均年龄为（34.04±9.21）岁。HPV疫苗接种率为44.70%,以20~<30岁年龄段接种率最高,接种率为50.8%（95%CI：45.6%~56.0%）,60~<70岁年龄段接种率最低,HPV疫苗接种率在各年龄段之间差异有统计学意义（P<0.05）。影响HPV疫苗接种的相关因素分析显示,年龄更小、居住在城镇地区、已婚状态、受教育水平、家庭年收入更高的HPV疫苗接种率高（均P<0.05）,尚不能确定宫颈癌家族史、生殖道炎症病史、感染过HPV是HPV疫苗接种的影响因素（均P>0.05）。结论深圳市龙岗区社区女性HPV疫苗接种率较低,在后续HPV疫苗接种的推广过程中,需要重点加强受教育水平较低、收入较低等相关女性人群的健康教育引导和相关的政策扶植。

关键词: 人乳头瘤病毒疫苗, 接种率, 社区女性, 影响因素

Abstract: Objective To understand the current status of human papillomavirus（HPV） vaccination and its influencing factors among women in Shenzhen community,and to provide reference for HPV vaccination promotion among women in community. Methods Using a combination of convenience sampling and stratified cluster sampling,1208 women from six street communities in Longgang District,Shenzhen were selected as the survey subjects. A questionnaire survey on the current status of HPV vaccination and its influencing factors was conducted among the sampled population from September to December 2023,and the data were analyzed. Results The average age of the included study subjects was （34.04±9.21）years. The HPV vaccination rate was 44.70%,and the vaccination rate was the highest in the the age group of 20-<30 years old,at 50.8%（95%CI：45.6%-56.0%）,and the lowest in the age group of 60-<70 years old. There was a statistically significant differences in HPV vaccination rate among different age groups（P<0.05）. The analysis of factors affecting HPV vaccination showed that the HPV vaccination rate was higher in those who were younger,living in urban areas,married,with higher education level and higher annual household income（all P<0.05）. However,family history of cervical cancer,history of genital tract inflammation and history of HPV infection were not factors affecting HPV vaccination（all P>0.05）. Conclusion The HPV vaccination rate was low among women in Longgang District of Shenzhen. Health education and related policy support should be strengthened in the subsequent promotion of HPV vaccination among women with lower education level and lower income.

Key words: Human papillomavirus vaccine, Vaccination rate, Community women, Influencing factor

中图分类号:

R186

蔡松涛, 梁文涛, 林锦波, 黄向辉, 洪国庆. 深圳市龙岗区社区女性人乳头瘤病毒疫苗的接种现状及其影响因素分析. [J]职业与健康, 2025, 41(15): 2042-2046.

CAI Songtao, LIANG Wentao, LIN Jinbo, HUANG Xianghui, HONG Guoqin. Analysis of the current status and influencing factors of human papillomavirus vaccination among community women in Longgang District of Shenzhen. [J]OCCUPATION AND HEALTH, 2025, 41(15): 2042-2046.

参考文献

[1] BUSKWOFIE A,DAVID-WEST G,CLARE C A.A review of cervical cancer:Incidence and disparities[J].J Natl Med Assoc,2020,112(2):229-232.
[2] EM B.Human papillomavirus and cervical cancer[J].Clin Microbiol Rev, 2003,16(1):1-17.
[3] VU M,YU J,AWOLUDE O A,et al.Cervical cancer worldwide[J].Curr Probl Cancer,2018,42(5):457-465.
[4] 王秀英,崔芹,韩利伟,等.高危型人乳头瘤病毒感染与宫颈上皮内瘤变的相关性[J].中华医院感染学杂志,2024,34(8):1222-1226.
[5] 卢林丽,方佳琦,阴建,等.人乳头瘤病毒疫苗的研究现状与展望[J].中国肿瘤,2024,33(2):153-160.
[6] WORLD MEDICAL ASSOCIATION.World medical association declaration of Helsinki:Ethical principles for medical research involving human subjects[J].JAMA,2013,310(20):2191-2194.
[7] 陈慧,张荣,刘春容,等.我国西部地区城市和农村中学生对人乳头瘤病毒及其预防性疫苗的认知及态度调查[J].现代预防医学,2020, 47(13):2400-2404.
[8] SIMMS K T,STEINBERG J,CARUANA M,et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries,2020-99:A modelling study[J].Lancet Oncol,2019,20(3):394-407.
[9] 田国良,郝雨欣,王继伟.人乳头瘤病毒疫苗的研究现状及接种政策[J].上海预防医学,2024,36(3):297-302.
[10] PITISUTTTHUM P,VELICER C,LUXEMBOURG A.9-Valent HPV vaccine for cancers,pre-cancers and genital warts related to HPV[J].Expert Rev Vaccines,2015,14(11):1405-1419.
[11] 罗雅娟,王丹丹,杨清.HPV致女性生殖道疾病及HPV疫苗现况[J].国际生殖健康/计划生育杂志,2019,38(3):244-248.
[12] 宋祎凡,刘晓雪,尹遵栋,等.2018—2020年中国9~45岁女性人乳头瘤病毒疫苗估算接种率[J].中国疫苗和免疫,2021,27(5):570-575.
[13] OLIVER K,FRAWLEY A,GARLAND E.HPV vaccination:Population approaches for improving rates[J].Hum Vaccin Immunother,2016, 12(6):1589-1593.
[14] PRABHU V S,BANSAL N,LIU Z,et al.HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States[J].BMC Public Health,2021,21(1):1-9.
[15] GOPALANI S V,JANITZ A E,BURKHART M,et al.HPV vaccination coverage and factors among american indians in cherokee nation[J].Cancer Causes Control,2023,34(3):267-275.
[16] 张雨晴,姜晓红,吴江平,等.江苏省南京市1 724例孕前女性HPV疫苗接种现状及其影响因素分析[J].中国妇幼卫生杂志,2022, 13(6):30-34.
[17] LI S L,LAU Y L,LAM T H,et al.HPV vaccination in Hong Kong:Uptake and reasons for non-vaccination amongst Chinese adolescent girls[J].Vaccine,2013,31(49):5785-5798.
[18] ARBYN M,WEIDERPASS E,BRUNI L,et al.Estimates of incidence and mortality of cervical cancer in 2018:A worldwide analysis[J].Lancet Glob Health,2020,8(2):e191-e203.
[19] CHRYSOSTOMOU A C,STYLIANOU D C,CONSTANTINIDOU A,et al.Cervical cancer screening programs in europe:the transition towards HPV vaccination and population-based HPV testing[J].Viruses,2018, 10(12):729-764.
[20] WASER M,HEISS R,BORENA W.Factors affecting children's HPV vaccination in Austria:Evidence from a parent survey[J].Hum Vaccin Immunother,2022,18(6):e1-e11.
[21] SMITH M A,HALL M,LEW J B,et al.Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities:Example from New Zealand[J].Vaccine,2018,36(42):6314-6324.
[22] 袁丽,储爱琴,徐安岚,等.育龄女性人乳头瘤病毒疫苗预防接种现状及影响因素分析[J].国际生殖健康/计划生育杂志,2020,39(3):210-212.
[23] 罗丽红,张海燕,钟洁.广东省惠东县女性宫颈癌认知及HPV疫苗接种现状分析[J].中国卫生工程学,2021,20(1):73-75.
[24] 程冉冉. 邯郸市适龄期女性HPV疫苗认知情况和接种现状调查研究[J].科技风,2021(4):148-149.
[25] 刘捷宸,吴琳琳,白庆瑞,等.上海市2017—2019年人乳头瘤病毒疫苗接种率和疑似预防接种异常反应监测[J].中国疫苗和免疫,2020, 26(3):322-325,348.
[26] 张师前,王凯,张远丽.HPV疫苗在中国的应用现状[J].中国实用妇科与产科杂志,2019,35(10):1090-1095.
[27] SIMMS K T,STEINBERG J,CARUANA M,et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries,2020-99:A modelling study[J].Lancet Oncol,2019,20(3):394-407.
[28] MCCORMACK P L.Quadrivalent human papillomavirus(types 6,11,16, 18) recombinant vaccine(gardasil^®):A review of its use in the prevention of premalignant anogenital lesions,cervical and anal cancers,and genital warts[J].Drugs,2014,74(11):1253-1283.
[29] NTANASIS-S I,KYRIAZOGLOU A,LIONTOS M,et al.Current trends in the management and prevention of human papillomavirus(HPV) infection[J].J BUON,2020,25(3):1281-1285.
[30] GRAVITT P E,WINER R L.Natural history of HPV infection across the lifespan:Role of viral latency[J].Viruses,2017,9(10):267-277.